Ed­i­tas' CRISPR-based eye ther­a­py proves safe, but the ju­ry's still out on whether it works

Re­searchers at Ed­i­tas Med­i­cine re­vealed long-an­tic­i­pat­ed da­ta for their CRISPR gene edit­ing pro­gram Wednes­day morn­ing, the sec­ond-ever batch of hu­man re­sults for in vi­vo ad­min­is­tra­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER